Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and
characterized in 1999. It is required for the generation of all monomeric forms of amyloid-β …

Alzheimer disease (AD) is the most common cause of dementia in older individuals (> 65
years) and has a long presymptomatic phase. Preventive therapies for AD are not yet …

BACKGROUND. Noninvasive detection of Alzheimer's disease (AD) with high specificity and
sensitivity can greatly facilitate identification of at-risk populations for earlier, more effective …

Since its discovery in 1984, the beta amyloid peptide has treaded the boards of
neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade …

The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1
(BACE1), initiates the production of the toxic amyloid β (Aβ) that plays a crucial early part in …

Autophagic dysregulation has been suggested in a broad range of neurodegenerative
diseases including age-related macular degeneration (AMD). To test whether the autophagy …

Abstract β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase
enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely …

β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's
disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 …

BACE1 (β-secretase, memapsin 2, Asp2) has emerged as a promising target for the
treatment of Alzheimer's disease. BACE1 is an aspartic protease which functions in the first …